Pulido CM, Quiram PA. Current understanding and management of aggressive posterior retinopathy of prematurity. World J Ophthalmol 2015; 5(2): 73-79 [DOI: 10.5318/wjo.v5.i2.73]
Corresponding Author of This Article
Polly A Quiram, MD, PhD, VitreoRetinal Surgery, P.A., 7760 France Ave S, Suite 310, Minneapolis, MN 55435, United States. pollyquiram@yahoo.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Ophthalmol. May 12, 2015; 5(2): 73-79 Published online May 12, 2015. doi: 10.5318/wjo.v5.i2.73
Current understanding and management of aggressive posterior retinopathy of prematurity
Christine M Pulido, Polly A Quiram
Christine M Pulido, Polly A Quiram, VitreoRetinal Surgery, P.A., Minneapolis, MN 55435, United States
Author contributions: Quiram PA and Pulido CM equally contributed to this paper.
Conflict-of-interest: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Polly A Quiram, MD, PhD, VitreoRetinal Surgery, P.A., 7760 France Ave S, Suite 310, Minneapolis, MN 55435, United States. pollyquiram@yahoo.com
Telephone: +1-952-9291131
Received: November 29, 2014 Peer-review started: November 29, 2014 First decision: December 12, 2014 Revised: January 12, 2015 Accepted: March 4, 2015 Article in press: March 5, 2015 Published online: May 12, 2015 Processing time: 171 Days and 6.7 Hours
Abstract
Aggressive posterior retinopathy of prematurity (ROP), previously referred to as “Rush disease”, is a rapidly progressive form of ROP. This form of ROP typically presents in very low birth weight babies of early gestational age. Historically, anatomical and functional outcomes have been poor with standard treatment. This review is designed to discuss current knowledge and treatment regarding this aggressive form of ROP. Recommendations regarding management of these difficult cases are detailed.
Core tip: Neonates with aggressive posterior retinopathy of prematurity often have unfavorable visual outcomes due to the aggressive and destructive nature of the disease. Treatment options, including laser and anti-vascular endothelial growth factor therapy can change the course of the disease, but both with potential side effects. Case studies and recommendations regarding the management of these complicated cases are reviewed.
